INmune Bio Inc. is a clinical-stage biotechnology company focused on developing therapies that target the innate immune system. The company operates through three product platforms: XPro (pegipanermin), a dominant-negative tumor necrosis factor (TNF) inhibitor designed to selectively neutralize soluble TNF in neuroinflammation-driven conditions such as Alzheimer's disease and treatment-resistant depression; INKmune, a cell-based medicine intended to prime natural killer cells against cancer; and CORDStrom, an allogeneic, umbilical cord-derived mesenchymal stromal cell platform whose lead product, Ebstrocel, is being developed for recessive dystrophic epidermolysis bullosa (RDEB).
As a pre-revenue company, INmune Bio's valuation is driven primarily by clinical data readouts, regulatory milestones, and its cash position. Investors follow the stock for its differentiated neuroinflammation approach in Alzheimer's disease and its nearer-term regulatory opportunity in the rare pediatric disease RDEB. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, INMB shares declined approximately 34%, falling from a closing price of $1.60 on October 14 to $1.05 in recent trading. The decline was not linear: the stock drifted lower through late October before accelerating sharply in early November, coinciding with the company's third-quarter earnings report and updated regulatory guidance.
The quarterly picture is even more pronounced. From the low-to-mid $2 range in mid-August, when the stock traded near $2.17, shares have fallen more than 50%. After peaking around $2.60 on an intraday basis in early September, the stock has been in a sustained downtrend, giving back most of its 2026 gains and signaling a meaningful shift in investor sentiment.
The sharpest pressure came from the company's regulatory timeline and financial disclosures. In October, INmune Bio announced it had submitted its final pre-MAA package to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and revised its strategy to submit a complete Marketing Authorization Application for Ebstrocel in early February 2027, rather than the earlier-anticipated submission window. The shift pushed potential U.K. approval to mid-2027, a delay that weighed on a stock already sensitive to milestone timing.
Third-quarter 2026 results, reported in early November, added to the sell-off. The company posted a net loss of $4.7 million, reported cash and cash equivalents of $16.3 million as of September 30, 2026, and indicated that significant company-funded development of XPro would be deferred until after Ebstrocel approval or a strategic partnership. Management also referenced October financing proceeds when describing its projected cash runway through the third quarter of 2027, a signal that capital-raising activity contributed to dilution concerns. The combination of a delayed lead program, deferred Alzheimer's spending, and a shrinking cash balance drove the stock lower.
The broader three-month decline reflects a recalibration of expectations around INmune Bio's pipeline. Earlier in 2026, the company secured FDA alignment on an integrated Phase 2b/3 registrational pathway for XPro in early Alzheimer's disease and received Fast Track designation, helping lift the stock into the mid-$2 range. Since then, the company has prioritized Ebstrocel and the RDEB regulatory path while deferring its Alzheimer's program, reducing the near-term catalysts that had previously supported the valuation.
At the same time, a declining cash position and financing activity have reminded investors of the execution and capital risks inherent to pre-revenue biotechnology. With no product approved and revenue still not realized, the quarterly slide reflects both a narrower near-term catalyst set and broader caution around clinical-stage biotech financing conditions. From what I see, this kind of recalibration is common in the sector when timelines shift.
The most important catalyst for INmune Bio is the completion and submission of its full Marketing Authorization Application for Ebstrocel, targeted for early February 2027. MHRA acceptance, review progress, and any requests for additional information will be closely watched, as will the planned U.S. Type B meeting and subsequent Biologics License Application timing. The confirmatory Phase 3 trial for Ebstrocel is expected to open in the first quarter of 2027.
Investors should also monitor the company's cash position and any additional financing activity, given the runway projection through the third quarter of 2027. Progress on the deferred XPro Alzheimer's program, including any partnership or additional funding, and updates on named-patient supply arrangements through the Uniphar agreement, represent other factors that could influence the stock. As always with clinical-stage biotech, regulatory outcomes, trial data, and capital availability remain the primary risks. I'm watching this closely as the next few months unfold.
In my own work, I’ve found Tickeron’s AI Trading Bots helpful for spotting systematic patterns across volatile names like INMB. The platform lets me compare automated strategies without building everything from scratch, which adds a useful layer when reviewing pre-revenue biotechs. It’s one of the tools I check periodically to see how different models are positioned in the current environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where INMB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMB advanced for three days, in 200 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for INMB turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 43 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for INMB entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.540) is normal, around the industry mean (3.498). P/E Ratio (-1.823) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (714.286) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. INMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapies that harness the patient's immune system to treat cancer
Industry Biotechnology